We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App

Novel Non-Invasive Liquid Biopsy Assay Enables Monitoring of Multiple Myeloma Patients

By LabMedica International staff writers
Posted on 28 Sep 2023
Print article
Image: M-inSight provides deeper insights into Multiple Myeloma monitoring (Photo courtesy of Sebia)
Image: M-inSight provides deeper insights into Multiple Myeloma monitoring (Photo courtesy of Sebia)

Multiple myeloma ranks as the second most common type of blood cancer, affecting a global population of over 170,000. This cancer targets plasma cells, which primarily exist in the bone marrow, and leads to their uncontrolled growth. Managing multiple myeloma is particularly challenging because patients often experience relapses, making it an incurable condition. A crucial aspect in monitoring this disease is the concept of Minimal Residual Disease (MRD), which refers to the undetectable traces of cancer cells that remain in the bone marrow post-treatment and can eventually cause a relapse. MRD status serves as a vital indicator of how well a treatment is working and could influence future treatment choices.

To enhance the management of multiple myeloma, especially as new treatments are being developed, there's an immediate need for more sensitive MRD tests that can be done through blood samples. Current tests usually require bone marrow samples, which are invasive to collect and not practical for regular check-ups. To fulfill this need, Sebia (Paris, France) has launched M-inSight, its serum-based MRD test for monitoring multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, which is a CAP-accredited, CLIA-licensed clinical laboratory and part of the Sebia Group.

M-inSight is a personalized, targeted mass spectrometry assay that is designed to detect the monoclonal protein (M-protein) secreted by the patient’s tumor cells in serum with unprecedented sensitivity. The technology is based on clonotypic peptides mass spectrometry, which avoids the interference with the polyclonal background leading to an ultra-sensitive test. Currently, Sebia is the only global partner covering the process of M-protein testing from initial detection to MRD and is also developing other liquid biopsy tests such as Circulating Tumor Cells (CTC) and new biomarkers.

“We are proud to launch M-inSight to improve the management of multiple myeloma and quality of life for patients, as well as assisting in the drug development and validation process”, said Dr. Pierre Sonigo, chief scientific officer at Sebia. “By testing in serum with equivalent sensitivity to bone marrow, we will solve current challenges in multiple myeloma MRD-testing, allowing for a more frequent and reliable monitoring of response to treatment.”

Related Links:

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Rapid Flu Test
Influenza A&B Rapid Test Kit
Complement 3 (C3) Test
GPP-100 C3 Kit
Motorized Pipette Controller

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.